Giese, Alf

[["dc.bibliographiccitation.firstpage","333"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Acta Neurochirurgica"],["dc.bibliographiccitation.lastpage","343"],["dc.bibliographiccitation.volume","152"],["dc.contributor.author","Kantelhardt, Sven Rainer"],["dc.contributor.author","Fadini, Tommaso"],["dc.contributor.author","Finke, Markus"],["dc.contributor.author","Kallenberg, Kai"],["dc.contributor.author","Siemerkus, Jakob"],["dc.contributor.author","Bockermann, Volker"],["dc.contributor.author","Matthaeus, Lars"],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Schweikard, Achim"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Giese, Alf"],["dc.date.accessioned","2018-11-07T08:45:57Z"],["dc.date.available","2018-11-07T08:45:57Z"],["dc.date.issued","2010"],["dc.description.abstract","Shape and exact location of motor cortical areas varies among individuals. The exact knowledge of these locations is crucial for planning of neurosurgical procedures. In this study, we have used robot-assisted image-guided transcranial magnetic stimulation (Ri-TMS) to elicit MEP response recorded for individual muscles and reconstruct functional motor maps of the primary motor cortex. One healthy volunteer and five patients with intracranial tumors neighboring the precentral gyrus were selected for this pilot study. Conventional MRI and fMRI were obtained. Transcranial magnetic stimulation was performed using a MagPro X100 stimulator and a standard figure-of-eight coil positioned by an Adept Viper s850 robot. The fMRI activation/Ri-TMS response pattern were compared. In two cases, Ri-TMS was additionally compared to intraoperative direct electrical cortical stimulation. Maximal MEP response of the m. abductor digiti minimi was located in an area corresponding to the \"hand knob\" of the precentral gyrus for both hemispheres. Repeated Ri-TMS measurements showed a high reproducibility. Simultaneous registration of the MEP response for m. brachioradialis, m. abductor pollicis brevis, and m. abductor digiti minimi demonstrated individual peak areas of maximal MEP response for the individual muscle groups. Ri-TMS mapping was compared to the corresponding fMRI studies. The areas of maximal MEP response localized within the \"finger tapping\" activated areas by fMRI in all six individuals. Ri-TMS is suitable for high resolution non-invasive preoperative somatotopic mapping of the motor cortex. Ri-TMS may help in the planning of neurosurgical procedures and may be directly used in navigation systems."],["dc.description.sponsorship","EC [MEST-CT-2004-504193]"],["dc.identifier.doi","10.1007/s00701-009-0565-1"],["dc.identifier.isi","000274199900024"],["dc.identifier.pmid","19943069"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4040"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20575"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0001-6268"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Robot-assisted image-guided transcranial magnetic stimulation for somatotopic mapping of the motor cortex: a clinical pilot study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1427"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Acta Neurochirurgica"],["dc.bibliographiccitation.lastpage","1434"],["dc.bibliographiccitation.volume","153"],["dc.contributor.author","Neulen, Axel"],["dc.contributor.author","Kantelhardt, Sven Rainer"],["dc.contributor.author","Pilgram-Pastor, Sara M."],["dc.contributor.author","Metz, Imke"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Giese, Alf"],["dc.date.accessioned","2018-11-07T08:54:37Z"],["dc.date.available","2018-11-07T08:54:37Z"],["dc.date.issued","2011"],["dc.description.abstract","Background Surgery for symptomatic sacral perineural cysts remains an issue of discussion. Assuming micro-communications between the cyst and thecal sac resulting in a valve mechanism and trapping of CSF as a pathomechanism, microsurgical fenestration from the cyst to the thecal sac was performed to achieve free CSF communication. Methods In 13 consecutive patients (10 female, 3 male), MRI revealed sacral perineural cysts and excluded other pathologies. Micro-communication between the thecal sac and the cysts was shown by delayed contrast filling of the cysts on postmyelographic CT. Surgical fenestration achieved free CSF communication between the thecal sac and cysts in all patients. The patient histories, follow-up examinations and self-assessment scales were analyzed. Symptoms at initial presentation included lumbosacral pain, pseudoradicular symptoms, genital pain and urinary dysfunction. Mean follow-up was 10.7 +/- 6.6 months. Findings Besides one CSF fistula, no surgical complications were observed. Five patients did not improve after surgery\\; in four of these cases multiple cysts were found, but small and promptly filling cysts remained untreated. Seven patients reported lasting benefit following surgery\\; three of these had single cysts, and all had cysts >1 cm. One patient initially benefited from cyst fenestration but experienced recurrent pain within 2 months postoperatively. Re-myelography revealed delayed contrast filling of the recurrent cyst\\; however, surgical revision did not lead to an improvement despite successful fenestration and collapse of the cyst revealed by postoperative imaging. Conclusions Microsurgical fenestration of sacral perineural cysts to the thecal sac is a surgical approach that has shown success in the treatment of lumbosacral pain, pseudoradicular symptoms, genital pain and urinary dysfunction associated with sacral perineural cysts. Our analysis, however, shows that mainly patients with singular large cysts benefit from this treatment."],["dc.identifier.doi","10.1007/s00701-011-1043-0"],["dc.identifier.isi","000292924700009"],["dc.identifier.pmid","21562735"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6644"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22710"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0001-6268"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Microsurgical fenestration of perineural cysts to the thecal sac at the level of the distal dural sleeve"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","441"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Neurosurgical Review"],["dc.bibliographiccitation.lastpage","449"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Bock, Hans Christoph"],["dc.contributor.author","Puchner, Maximilian Josef Anton"],["dc.contributor.author","Lohmann, Frauke"],["dc.contributor.author","Schuetze, Michael"],["dc.contributor.author","Koll, Simone"],["dc.contributor.author","Ketter, Ralf"],["dc.contributor.author","Buchalla, Ruediger"],["dc.contributor.author","Rainov, Nikolai"],["dc.contributor.author","Kantelhardt, Sven Rainer"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Giese, Alf"],["dc.date.accessioned","2018-11-07T08:38:45Z"],["dc.date.available","2018-11-07T08:38:45Z"],["dc.date.issued","2010"],["dc.description.abstract","Randomized phase III trials have shown significant improvement of survival 1, 2, and 3 years after implantation of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers for patients with newly diagnosed malignant glioma. But these studies and subsequent non-phase III studies have also shown risks associated with local chemotherapy within the central nervous system. The introduction of concomitant radiochemotherapy with temozolomide (TMZ) has later demonstrated a survival benefit in a phase III trial and has become the current treatment standard for newly diagnosed malignant glioma patients. Lately, this has resulted in clinical protocols combining local chemotherapy with BCNU wafers and concomitant radiochemotherapy with TMZ although this may carry the risk of increased toxicity. We have compiled the treatment experience of seven neurosurgical centers using implantation of carmustine wafers at primary surgery followed by 6 weeks of radiation therapy (59-60 Gy) and 75 mg/m(2)/day TMZ in patients with newly diagnosed glioblastoma followed by TMZ monochemotherapy. We have retrospectively analyzed the postoperative clinical course, occurrence and severity of adverse events, progression-free interval, and overall survival in 44 patients with newly diagnosed glioblastoma multiforme. All patients received multimodal treatment including tumor resection, BCNU wafer implantation, and concomitant radiochemotherapy. Of 44 patients (mean age 59 +/- 10.8 years) with glioblastoma who received Gliadel wafer at primary surgery, 28 patients (64%) had died, 16 patients (36%) were alive, and 15 patients showed no evidence of clinical or radiographic progression after a median follow-up of 15.6 months. At time of analysis of adverse events in this patient population, the median overall survival was 12.7 months and median progression-free survival was 7.0 months. Surgical, neurological, and medical adverse events were analyzed. Twenty-three patients (52%) experienced adverse events of any kind including complications that did not require treatment. Nineteen patients (43%) experienced grade 3 or grade 4 adverse events. Surgical complications included cerebral edema, healing abnormalities, cerebral spinal fluid leakage, meningitis, intracranial abscess, and hydrocephalus. Neurological adverse events included newly diagnosed seizures, alteration of mental status, and new neurological deficits. Medical complications were thromboembolic events (thrombosis, pulmonary embolism) and hematotoxicity. Combination of both treatment strategies, local chemotherapy with BCNU wafer and concomitant radiochemotherapy, appears attractive in aggressive multimodal treatment schedules and may utilize the sensitizing effect of TMZ and carmustine on MGMT and AGT on their respective drug resistance genes. Our data demonstrate that combination of local chemotherapy and concomitant radiochemotherapy carries a significant risk of toxicity that currently appears underestimated. Adverse events observed in this study appear similar to complication rates published in the phase III trials for BCNU wafer implantation followed by radiation therapy alone, but further add the toxicity of concomitant radiochemotherapy with systemic TMZ. Save use of a combined approach will require specific prevention strategies for multimodal treatments."],["dc.identifier.doi","10.1007/s10143-010-0280-7"],["dc.identifier.isi","000282843600013"],["dc.identifier.pmid","20706757"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18832"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0344-5607"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2241"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Acta Neurochirurgica"],["dc.bibliographiccitation.lastpage","2250"],["dc.bibliographiccitation.volume","153"],["dc.contributor.author","Neulen, Axel"],["dc.contributor.author","Gutenberg, Angelika"],["dc.contributor.author","Takacs, Ildiko"],["dc.contributor.author","Weber, Gyoergy"],["dc.contributor.author","Wegmann, Juergen"],["dc.contributor.author","Schulz-Schaeffer, Walter J."],["dc.contributor.author","Giese, Alf"],["dc.date.accessioned","2018-11-07T08:50:27Z"],["dc.date.available","2018-11-07T08:50:27Z"],["dc.date.issued","2011"],["dc.description.abstract","Semisynthetic collagen matrices are promising duraplasty grafts with low risk of cerebrospinal fluid (CSF) fistulas, good tissue integration and minor foreign body reaction. The present study investigates the efficacy and biocompatibility of a novel semisynthetic bilayered collagen matrix (BCM, B. Braun Aesculap) as dural onlay graft for duraplasty. Thirty-four pigs underwent osteoclastic trepanation, excision of the dura, and placement of a cortical defect, followed by duraplasty using BCM, Suturable DuraGen (TM) (Integra Neuroscience), or periosteum. CSF tightness and intraoperative handling of the grafts were evaluated. Pigs were sacrificed after 1 and 6 months for histological analysis. BCM and DuraGen (TM) showed superior handling than periosteum with a trend for better adhesion to dura and CSF tightness for BCM. Periosteum, which was sutured unlike the synthetic grafts, had the highest intraoperative CSF tightness. Duraplasty time with periosteum was significantly higher (14.4 +/- 2.7 min) compared with BCM (2.8 +/- 0.8 min) or DuraGen (TM) (3.0 +/- 0.5 min). Tissue integration by fibroblast infiltration was observed after 1 month for all devices. More adhesions between graft and cortex were observed with DuraGen (TM) compared with BCM and periosteum. No relevant adhesions between leptomeninges and BCM were observed and all devices showed comparable lymphocytic reaction of the brain. All devices were completely integrated after 6 months. BCM and DuraGen (TM) showed a trend for an enhanced lymphocytic reaction of the brain parenchyma compared with periosteum. Implant rejection was not observed. Semisythetic collagen matrices are an attractive alternative in duraplasty due to their easy handling, lower surgical time, and high biocompatibility."],["dc.description.sponsorship","B. Braun Aesculap AG, Tuttlingen, Germany"],["dc.identifier.doi","10.1007/s00701-011-1059-5"],["dc.identifier.isi","000296083700019"],["dc.identifier.pmid","21739175"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7137"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21696"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0001-6268"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Evaluation of efficacy and biocompatibility of a novel semisynthetic collagen matrix as a dural onlay graft in a large animal model"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","655"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Acta Neurochirurgica"],["dc.bibliographiccitation.lastpage","661"],["dc.bibliographiccitation.volume","152"],["dc.contributor.author","Kantelhardt, Sven Rainer"],["dc.contributor.author","Bock, Hans Christoph"],["dc.contributor.author","Siam, Laila"],["dc.contributor.author","Larsen, Joerg"],["dc.contributor.author","Burger, Ralf"],["dc.contributor.author","Schillinger, Wolfgang"],["dc.contributor.author","Bockermann, Volker"],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Giese, Alf"],["dc.date.accessioned","2018-11-07T08:44:14Z"],["dc.date.available","2018-11-07T08:44:14Z"],["dc.date.issued","2010"],["dc.description.abstract","In contrast to other regions of the human spine, dorsal fixation with rods and pedicle screws is comparatively rarely performed in the cervical spine. Although this technique provides a higher mechanical strength than the more frequently used lateral mass screws, many surgeons fear the relatively high rate of misplacements. This higher incidence is mainly due to the complex vertebral anatomy in this spinal segment. For correct screw placement, the availability of an immediate and efficient intra-operative imaging tool to ascertain the accuracy of the pedicle screw hole position would be beneficial. We have previously investigated the usefulness of an intraspinal, specifically, intra-osseous ultrasound technique in the lumbar spine. In this study its accuracy as a means of controlling intrapedicular screw hole positioning has been evaluated in the cervical spine. An endovascular ultrasound transducer was used for the intra-luminal scanning of 54 pedicle screw holes in cadaveric human spine specimens. Twenty-three of these had been intentionally misplaced (cortex breached). The resulting image files were assessed by three investigators blinded to both the procedure and the corresponding CT findings. The investigators differentiated correctly between adequately and poorly placed pedicle screw holes in 96% of cases. False negatives and false positives both occurred in no more than 1.8% of cases. Intrapedicular ultrasonography of pedicle screw holes in the cervical spine is a promising technique for the intra-operative assessment of bore hole placement and may increase operative safety and postoperative outcome in posterior cervical fusion surgery."],["dc.identifier.doi","10.1007/s00701-009-0447-6"],["dc.identifier.isi","000275945600013"],["dc.identifier.pmid","19597760"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4182"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20152"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0001-6268"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Intra-osseous ultrasound for pedicle screw positioning in the subaxial cervical spine: an experimental study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e11323"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Kantelhardt, Sven Rainer"],["dc.contributor.author","Caarls, Wouter"],["dc.contributor.author","de Vries, Anthony H. B."],["dc.contributor.author","Hagen, Guy M."],["dc.contributor.author","Jovin, Thomas M."],["dc.contributor.author","Schulz-Schaeffer, Walter J."],["dc.contributor.author","Rohde, Veit"],["dc.contributor.author","Giese, Alf"],["dc.contributor.author","Arndt-Jovin, Donna J."],["dc.date.accessioned","2018-11-07T08:42:07Z"],["dc.date.available","2018-11-07T08:42:07Z"],["dc.date.issued","2010"],["dc.description.abstract","Background: The current therapy of malignant gliomas is based on surgical resection, radio-chemotherapy and chemotherapy. Recent retrospective case-series have highlighted the significance of the extent of resection as a prognostic factor predicting the course of the disease. Complete resection in low-grade gliomas that show no MRI-enhanced images are especially difficult. The aim in this study was to develop a robust, specific, new fluorescent probe for glioma cells that is easy to apply to live tumor biopsies and could identify tumor cells from normal brain cells at all levels of magnification. Methodology/Principal Findings: In this investigation we employed brightly fluorescent, photostable quantum dots (QDs) to specifically target epidermal growth factor receptor (EGFR) that is upregulated in many gliomas. Living glioma and normal cells or tissue biopsies were incubated with QDs coupled to EGF and/or monoclonal antibodies against EGFR for 30 minutes, washed and imaged. The data include results from cell-culture, animal model and ex vivo human tumor biopsies of both low-grade and high-grade gliomas and show high probe specificity. Tumor cells could be visualized from the macroscopic to single cell level with contrast ratios as high as 1000: 1 compared to normal brain tissue. Conclusions/Significance: The ability of the targeted probes to clearly distinguish tumor cells in low-grade tumor biopsies, where no enhanced MRI image was obtained, demonstrates the great potential of the method. We propose that future application of specifically targeted fluorescent particles during surgery could allow intraoperative guidance for the removal of residual tumor cells from the resection cavity and thus increase patient survival."],["dc.identifier.doi","10.1371/journal.pone.0011323"],["dc.identifier.isi","000279370000006"],["dc.identifier.pmid","20614029"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6912"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19633"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 2.5"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.5"],["dc.title","Specific Visualization of Glioma Cells in Living Low-Grade Tumor Tissue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","805"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Radiology"],["dc.bibliographiccitation.lastpage","812"],["dc.bibliographiccitation.volume","253"],["dc.contributor.author","Kallenberg, Kai"],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Helms, Gunther"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Wrede, Arne"],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Giese, Alf"],["dc.contributor.author","Frahm, Jens"],["dc.contributor.author","Strik, Herwig"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Knauth, Michael"],["dc.date.accessioned","2018-11-07T11:21:46Z"],["dc.date.available","2018-11-07T11:21:46Z"],["dc.date.issued","2009"],["dc.description.abstract","Purpose: To use localized in vivo proton magnetic resonance (MR) spectroscopy of the contralateral hemisphere in patients with glioblastoma multiforme (GBM) to detect alterations in cerebral metabolites as potential markers of infiltrating GBM cells. Materials and Methods: The study was approved by the ethics committee, and written informed consent was obtained. Twenty-two patients with newly diagnosed and untreated GBM underwent in vivo single-voxel short echo time proton MR spectroscopy with a 3-T MR imaging system. Absolute metabolite concentrations in the hemisphere contralateral to the tumor were compared with data from five patients with low-grade gliomas (LGGs) and from a group of 14 age-matched control subjects by using analysis of variance and subsequent t tests or corresponding nonparametric tests. Results: In the contralateral hemisphere, MR spectroscopy revealed increased concentrations of myo-inositol and glutamine. Mean myo-inositol levels were significantly increased in patients with GBM (3.6 mmol/L +/- 0.8 [standard deviation]) relative to levels in control subjects (3.1 mmol/L +/- 0.6; P = .03) and tended to be higher relative to levels in patients with LGG (2.7 mmol/L +/- 0.8; P = .09). Mean glutamine concentrations in patients with GBM (3.4 mmol/L +/- 0.9) differed significantly from those in control subjects (2.7 mmol/L +/- 0.7; P < .01); mean concentrations in patients with GBM differed from those in patients with LGG (2.4 mmol/L +/- 0.5; P < .01). There were no significant differences between data in patients with LGG and in control subjects. Conclusion: Increased concentrations of myo-inositol and glutamine in the contralateral normal-appearing white matter of GBM patients are consistent with mild astrocytosis and suggest the detectability of early neoplastic infiltration by using proton MR spectroscopy in vivo. (C) RSNA, 2009"],["dc.identifier.doi","10.1148/radiol.2533071654"],["dc.identifier.isi","000272247300028"],["dc.identifier.pmid","19789222"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6268"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55854"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Radiological Soc North America"],["dc.relation.issn","0033-8419"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Untreated Glioblastoma Multiforme: Increased Myo-inositol and Glutamine Levels in the Contralateral Cerebral Hemisphere at Proton MR Spectroscopy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","43"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Translational oncology"],["dc.bibliographiccitation.lastpage","49"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Schmidt, Nils Ole"],["dc.contributor.author","Ziu, Mateo"],["dc.contributor.author","Cargioli, Theresa"],["dc.contributor.author","Westphal, Manfred"],["dc.contributor.author","Giese, Alf"],["dc.contributor.author","Black, Peter M."],["dc.contributor.author","Carroll, Rona S."],["dc.date.accessioned","2019-07-10T08:11:51Z"],["dc.date.available","2019-07-10T08:11:51Z"],["dc.date.issued","2010-02-01"],["dc.description.abstract","Thromboxane synthase (TXSA), an enzyme of the arachidonic acid metabolism, is upregulated in human glial tumors and is involved in glioma progression. Here, we analyzed the in vitro and in vivo effects of pharmacological inhibition of TXSA activity on human glioblastoma cells. Furegrelate, a specific inhibitor of TXSA, significantly inhibited tumor growth in an orthotopic glioblastoma model by inducing proapoptotic, antiproliferative, and antiangiogenic effects. Inhibition of TXSA induced a proapoptotic disposition of glioma cells and increased the sensitivity to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea, significantly prolonging the survival time of intracerebral glioma-bearing mice. Our data demonstrate that the targeted inhibition of TXSA activity improves the efficiency of conventional alkylation chemotherapy in vivo. Our study supports the role of TXSA activity for the progression of malignant glioma and the potential utility of its therapeutic modulation for glioma treatment."],["dc.identifier.pmid","20165694"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11289"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60809"],["dc.language.iso","en"],["dc.relation.issn","1936-5233"],["dc.rights","CC BY-NC-ND 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/3.0"],["dc.title","Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","241"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Neuro-Oncology"],["dc.bibliographiccitation.lastpage","249"],["dc.bibliographiccitation.volume","91"],["dc.contributor.author","Schauff, Anne Katrin"],["dc.contributor.author","Kim, Ella L."],["dc.contributor.author","Leppert, Jan"],["dc.contributor.author","Nadrowitz, Roger"],["dc.contributor.author","Wuestenberg, Robin"],["dc.contributor.author","Brockmann, Mark Alexander"],["dc.contributor.author","Giese, Alf"],["dc.date.accessioned","2018-11-07T08:33:12Z"],["dc.date.available","2018-11-07T08:33:12Z"],["dc.date.issued","2009"],["dc.description.abstract","The invasion- and apoptosis-associated thromboxane synthase gene encoding an enzyme of the arachidonic acid pathway has been implicated in glioma progression. Furegrelate, a specific inhibitor of thromboxane synthase, blocks cell motility, induces apoptosis and increases sensitivity to drug induced apoptosis in human glioma cells in vitro. The impact of furegrelate on the sensitivity of human glioma cells to gamma-irradiation was analyzed using colony formation assay in vitro and an orthotopic mouse model in vivo. Pre-treatment of glioma cells with furegrelate increases radiation sensitivity of cultured glioma cells. Treatment of experimental gliomas with suboptimal doses of radiation and furegrelate results in a significant decrease in tumor volumes compared to untreated controls. Thus, the specific thromboxane synthase inhibitor furegrelate increases death response induced by gamma-radiation in glioma cells in vitro and sensitizes experimental gliomas to radiation treatment in vivo."],["dc.description.sponsorship","Deutsche Krebshilfe [10-2166 Gi2]"],["dc.identifier.doi","10.1007/s11060-008-9708-0"],["dc.identifier.isi","000262241500001"],["dc.identifier.pmid","18825315"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3596"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17517"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0167-594X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0130519"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Barrantes-Freer, Alonso"],["dc.contributor.author","Renovanz, Mirjam"],["dc.contributor.author","Eich, Marcus"],["dc.contributor.author","Braukmann, Alina"],["dc.contributor.author","Sprang, Bettina"],["dc.contributor.author","Spirin, Pavel"],["dc.contributor.author","Pardo, Luis A."],["dc.contributor.author","Giese, Alf"],["dc.contributor.author","Kim, Ella L."],["dc.date.accessioned","2018-11-07T09:55:48Z"],["dc.date.available","2018-11-07T09:55:48Z"],["dc.date.issued","2015"],["dc.description.abstract","A transmembrane protein CD133 has been implicated as a marker of stem-like glioma cells and predictor for therapeutic response in malignant brain tumours. CD133 expression is commonly evaluated by using antibodies specific for the AC133 epitope located in one of the extracellular domains of membrane-bound CD133. There is conflicting evidence regarding the significance of the AC133 epitope as a marker for identifying stem-like glioma cells and predicting the degree of malignancy in glioma cells. The reasons for discrepant results between different studies addressing the role of CD133/AC133 in gliomas are unclear. A possible source for controversies about CD133/AC133 is the widespread assumption that expression patterns of the AC133 epitope reflect linearly those of the CD133 protein. Consequently, the readouts from AC133 assessments are often interpreted in terms of the CD133 protein. The purpose of this study is to determine whether and to what extent do the readouts obtained with anti-AC133 antibody correspond to the level of CD133 protein expressed in stem-like glioma cells. Our study reveals for the first time that CD133 expressed on the surface of glioma cells is poorly immunoreactive for AC133. Furthermore, we provide evidence that the level of CD133 occupancy on the surface of glioma cells fluctuates during the cell cycle. Our results offer a new explanation for numerous inconsistencies regarding the biological and clinical significance of CD133/AC133 in human gliomas and call for caution in interpreting the lack or presence of AC133 epitope in glioma cells."],["dc.identifier.doi","10.1371/journal.pone.0130519"],["dc.identifier.isi","000356567500111"],["dc.identifier.pmid","26086074"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11954"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36830"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]